Related Experiment Video
Updated: Mar 17, 2026
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Statins in Familial Hypercholesterolemia: Consequences for Coronary Artery Disease and All-Cause Mortality
Joost Besseling1, G Kees Hovingh1, Roeland Huijgen1
1Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands.
Insights
Statin therapy significantly reduced coronary artery disease (CAD) events and mortality by 44% in patients with heterozygous familial hypercholesterolemia (FH). This finding quantifies the benefit of statins for FH patients, aiding cost-effectiveness analyses.
Area of Science:
- Cardiology
- Pharmacology
- Genetics
Background:
- Quantifying the reduction in coronary artery disease (CAD) events and mortality attributed to statin use in patients with heterozygous familial hypercholesterolemia (FH) remains crucial.
- Heterozygous FH is a genetic disorder characterized by high cholesterol levels, increasing cardiovascular risk.
Purpose of the Study:
- To estimate the relative risk reduction for CAD events and all-cause mortality associated with statin therapy in adult patients diagnosed with heterozygous FH.
- To provide essential data for cost-effectiveness studies concerning FH management and the evaluation of novel lipid-lowering therapies.
Main Methods:
- A cohort of adult heterozygous FH patients, identified through the Dutch FH screening program (1994-2013) and free of CAD at baseline, was analyzed.
- Medical records were linked to track CAD events (myocardial infarction, revascularization) and mortality up to 2015.
- Cox proportional hazard models with inverse-probability-for-treatment weighting (IPTW) were employed to assess the time-varying effect of statins, adjusting for other medications.
Main Results:
- The study included 2,447 patients, with 1,559 meeting the criteria (1,041 statin users, 518 never-users).
- Statin users experienced significantly fewer CAD events and deaths compared to never-users (8.8 vs. 5.3 per 1,000 person-years, p < 0.001).
- After IPTW and adjustments, statin use was associated with a 44% reduction in the risk of CAD and all-cause mortality (Hazard Ratio: 0.56; 95% CI: 0.33 to 0.96).
Conclusions:
- Moderate- to high-intensity statin therapy demonstrably lowers the risk of CAD events and mortality by 44% in individuals with heterozygous FH.
- These findings underscore the significant clinical benefit of statins in this high-risk population.
- The quantified risk reduction is vital for informing economic evaluations and healthcare policy regarding FH treatment.
Background:
A statin-induced reduction of coronary artery disease (CAD) events and mortality has not been adequately quantified in patients with heterozygous familial hypercholesterolemia (FH).
Objectives:
This study estimated the relative risk reduction for CAD and mortality by statins in heterozygous FH patients.
Methods:
The authors included all adult heterozygous FH patients, identified by the Dutch screening program for FH between 1994 and 2013, who were free of CAD at baseline. Hospital, pharmacy, and mortality records between 1995 and 2015 were linked to these patients. The primary outcome was the composite of myocardial infarction, coronary revascularization, and death from any cause. The effect of statins (time-varying) was determined using a Cox proportional hazard model, while correcting for the use of other lipid-lowering therapy, thrombocyte aggregation inhibitors, and antihypertensive and antidiabetic medication. The authors applied inverse-probability-for-treatment weighting (IPTW) to account for differences at baseline between statin users and never-users.
Results:
The authors obtained medical records of 2,447 patients, of whom 888 were excluded on the basis of age <18 years or previous CAD. Simvastatin 40 mg and atorvastatin 40 mg accounted for 23.1% and 22.8% of all prescriptions, respectively. Statin users (n = 1,041) experienced 89 CAD events and 17 deaths during 11,674 person-years of follow-up versus statin never-users (n = 518), who had 22 CAD events and 9 deaths during 4,892 person-years (combined rates 8.8 vs. 5.3 per 1,000 person-years, respectively; p < 0.001). After applying IPTW and adjusting for other medications, the hazard ratio of statin use for CAD and all-cause mortality was 0.56 (95% confidence interval: 0.33 to 0.96).
Conclusions:
In patients with heterozygous FH, moderate- to high-intensity statin therapy lowered the risk for CAD and mortality by 44%. This is essential information in all cost-effectiveness studies of this disorder, such as when evaluating reimbursement of new lipid-lowering therapies.
More Related Videos
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:29Cholesterol: Significance and Regulation
Considering cholesterol and...
01:26Atherosclerosis III: Management
01:26Coronary Artery Disease IV: Preventive Measures
01:30Coronary Artery Disease I: Introduction
01:27Coronary Artery Disease V: Interprofessional Care